Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors

Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors

Summary: Pancreatic ductal adenocarcinoma (PDAC) shows limited response to chemotherapy, partly due to the absence of effective biomarkers for personalized treatment. Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 90% of PDAC cases, and tumors dependent on KRAS (dKRAS) can...

Full description

Saved in:
Bibliographic Details
Main Authors: Giorgia Anastasio, Michela Felaco, Alessia Lamolinara, Francesco del Pizzo, Elisa Cacciagrano, Carla Mottini, Margherita Mutarelli, Francesca Di Modugno, Manuela Iezzi, Luca Cardone
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:iScience
Subjects:
Pharmacology
Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004225001026
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589004225001026

Similar Items